SPDR S&P Biotech ETF (NYSEARCA:XBI – Get Free Report) was the target of unusually large options trading activity on Tuesday. Stock traders acquired 51,835 put options on the stock. This represents an increase of 41% compared to the typical daily volume of 36,668 put options.
Hedge Funds Weigh In On SPDR S&P Biotech ETF
Several large investors have recently added to or reduced their stakes in XBI. Bank of America Corp DE lifted its stake in shares of SPDR S&P Biotech ETF by 13.3% during the 1st quarter. Bank of America Corp DE now owns 14,518,027 shares of the exchange traded fund’s stock valued at $1,854,388,000 after buying an additional 1,700,851 shares in the last quarter. Avoro Capital Advisors LLC bought a new stake in SPDR S&P Biotech ETF during the fourth quarter valued at about $256,053,000. OMERS ADMINISTRATION Corp lifted its position in shares of SPDR S&P Biotech ETF by 42,425.2% in the fourth quarter. OMERS ADMINISTRATION Corp now owns 1,190,707 shares of the exchange traded fund’s stock valued at $145,147,000 after acquiring an additional 1,187,907 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its stake in shares of SPDR S&P Biotech ETF by 61.4% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 691,000 shares of the exchange traded fund’s stock worth $84,254,000 after acquiring an additional 263,000 shares during the period. Finally, Hsbc Holdings PLC grew its position in shares of SPDR S&P Biotech ETF by 7.8% during the fourth quarter. Hsbc Holdings PLC now owns 638,529 shares of the exchange traded fund’s stock worth $78,049,000 after purchasing an additional 46,339 shares in the last quarter.
SPDR S&P Biotech ETF Stock Up 0.1%
Shares of XBI opened at $154.18 on Thursday. The business has a 50-day simple moving average of $157.83 and a two-hundred day simple moving average of $142.39. SPDR S&P Biotech ETF has a 52 week low of $93.49 and a 52 week high of $169.89. The stock has a market cap of $10.07 billion, a price-to-earnings ratio of 11.47 and a beta of 0.84.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Further Reading
- Five stocks we like better than SPDR S&P Biotech ETF
- Analysts See Double-Digit Upside for These 3 Stocks
- 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
- Jackson’s Record Quarter Powers the Bull Case
- Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
